The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The report Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period.
Market Drivers: -
1 Growing Diabetic Population
2 Technological Advancements in Insulin Delivery Devices
3 Favorable Reimbursement Environment and Government Support in Selected Countries
4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices
Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092
By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure.
In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada.
During the forecast period, Asia-Pacific region is expected to register the highest growth rate. The high growth in the region can be attributed to the high adoption of insulin pens and approvals for injectable insulin in Japan, and the rising partnerships among the global and local players in Asia-Pacific countries are expected to support the growth of the Asia-Pacific insulin delivery devices market.
The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US).
